29,543 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Intech Investment Management LLC

Intech Investment Management LLC purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 29,543 shares of the company's stock, valued at approximately $861,000.

Several other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Denali Therapeutics by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 10,968,293 shares of the company's stock worth $225,069,000 after purchasing an additional 133,810 shares in the last quarter. Marshall Wace LLP increased its holdings in Denali Therapeutics by 12.7% during the 2nd quarter. Marshall Wace LLP now owns 2,418,833 shares of the company's stock valued at $56,165,000 after purchasing an additional 272,454 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Denali Therapeutics by 6.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,472 shares of the company's stock valued at $32,913,000 after purchasing an additional 84,522 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock worth $36,076,000 after purchasing an additional 149,939 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Denali Therapeutics in the second quarter valued at $24,454,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Stock Down 0.6 %

DNLI traded down $0.16 during trading on Friday, hitting $25.00. The company had a trading volume of 388,118 shares, compared to its average volume of 1,069,030. The firm's 50-day moving average price is $27.41 and its 200 day moving average price is $24.43. The company has a market capitalization of $3.60 billion, a PE ratio of -9.12 and a beta of 1.40. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same quarter last year, the business earned ($0.72) earnings per share. Sell-side analysts forecast that Denali Therapeutics Inc. will post -2.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

DNLI has been the subject of several research reports. Citigroup lifted their target price on Denali Therapeutics from $26.00 to $32.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. HC Wainwright restated a "buy" rating and set a $90.00 target price on shares of Denali Therapeutics in a research report on Thursday, November 7th. Wedbush lowered their price target on shares of Denali Therapeutics from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, August 2nd. Raymond James restated a "market perform" rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Finally, Jefferies Financial Group lifted their target price on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.90.

Insider Transactions at Denali Therapeutics

In other news, Director Vicki L. Sato sold 1,020 shares of the business's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the transaction, the director now directly owns 111,056 shares in the company, valued at $3,331,680. The trade was a 0.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steve E. Krognes sold 30,000 shares of the firm's stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the sale, the director now owns 29,096 shares of the company's stock, valued at $844,656.88. This trade represents a 50.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 86,578 shares of company stock worth $2,474,440 in the last 90 days. Corporate insiders own 7.90% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.